Sanjeevani Jain
Psychiatry · Sparta, NJNPI 1902887235
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,716 of the $16,016 with a category attached, or 73.2%. 31 manufacturers reported payments, led by AbbVie at 34.6% of the total. Reporting peaked in 2020 at $3,289 and has fallen 75.2% since, to $816 in 2025. Among psychiatry clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 932 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Otsuka America Pharmaceutical, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Lundbeck LLC$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Takeda Pharmaceuticals U.S.A., Inc.$630
- plus $4K from 25 others
What the payments were for
- Speaking & faculty fees$4,17526%
- Food & beverage$11,71673%
- Education$1251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 165 | $5,547 |
| Otsuka America Pharmaceutical, Inc. | 167 | $2,093 |
| Teva Pharmaceuticals USA, Inc. | 103 | $1,448 |
| Lundbeck LLC | 119 | $1,333 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 80 | $1,195 |
| Takeda Pharmaceuticals U.S.A., Inc. | 52 | $630 |
| Alkermes, Inc. | 46 | $542 |
| Neos Therapeutics, LP | 30 | $377 |
| Ironshore Pharmaceuticals Inc. | 8 | $377 |
| Jazz Pharmaceuticals Inc. | 14 | $301 |
| Sunovion Pharmaceuticals Inc. | 27 | $276 |
| Axsome Therapeutics, Inc. | 16 | $244 |
| Almatica Pharma LLC | 15 | $211 |
| Bausch Health US, LLC | 14 | $196 |
| Supernus Pharmaceuticals, Inc. | 14 | $186 |
| Novo Nordisk | 3 | $153 |
| Idorsia Pharmaceuticals US Inc | 11 | $145 |
| AstraZeneca | 1 | $125 |
| Tris Pharma Inc | 9 | $120 |
| Avanir Pharmaceuticals, Inc. | 6 | $84 |
| Eisai Inc. | 6 | $75 |
| Johnson & Johnson | 5 | $60 |
| Corium, LLC | 4 | $59 |
| Vertical Pharmaceuticals, LLC | 4 | $56 |
| Harmony Biosciences LLC | 3 | $42 |
| Shire North American Group Inc | 3 | $41 |
| Arbor Pharmaceuticals, Inc. | 2 | $28 |
| Vanda Pharmaceuticals Inc. | 2 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
| Adlon Therapeutics L.p. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$4,175
- Jornay PM 20mg capsules (Bottle of 100)$288
- REXULTI$229
- FARXIGA$125
- XYREM$125
- RYBELSUS$125
- CAPLYTA$125
- Austedo XR$123
- AUSTEDO$113
How this compares
$16,016 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 29 | $84,949 |
| RexultiBrexpiprazole | 18 | $25,559 |
| TrintellixVortioxetine Hydrobromide | 25 | $18,339 |
| VyvanseLisdexamfetamine Dimesylate | 18 | $6,805 |
| Divalproex Sodium ErDivalproex Sodium | 54 | $4,592 |
| Bupropion XlBupropion Hcl | 111 | $3,655 |
| Trazodone Hcl | 110 | $3,354 |
| Aripiprazole | 79 | $3,000 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 54 | $2,676 |
| Paroxetine ErParoxetine Hcl | 12 | $2,412 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 30 | $1,392 |
| Quetiapine Fumarate | 90 | $1,298 |
| Alprazolam | 173 | $1,156 |
| Duloxetine Hcl | 80 | $1,112 |
| Olanzapine | 58 | $1,108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $2,093 | $110,50847 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $630 | $25,14343 claims |
| Almatica Pharma LLCSertraline Hcl | $211 | $25868 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Other psychiatry in Sparta
- Marc CantillonLivingston$522K
- Robert BransfieldRed Bank$415K
- Erika ConcepcionLong Branch$354K
- Leon RosenbergCherry Hill$257K
- Lloyd AlceraMarlton$187K
- Gary SmallHackensack$170K
- Shankar SrinivasanParsippany$155K
- Matthew PiteraToms River$153K
- Boris BorodulinEast Brunswick$116K
- Anthony RostainCamden$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.